Saturday 30 April 2016

Week 38 Review

Yet another week that started off quite well and then fell apart on Friday. A rather irritating trend! Biggest loser this week was BLUR:Blur Group which fell 13% after fairly dire results. So happy that I bought such a small holding as these don't show any signs of improving. The other double-digit loser was MMX:Minds + Machines which fell 11% after spectacularly disappointing results. All had been quite upbeat recently, so I wasn't expecting a thumping great loss for the year. This threatens to be a value trap for some time now, although I still believe they will eventually return a profit. Just relieved I sold a batch for £20 profit a few weeks ago and liberated £500 that would have been trapped.

There were a few good performers this week. SXX:Sirrius Minerals climbed 12% and are almost in profit, and share of the week KIBO:Kibo Mining are finally starting to show their true quality, with an amazing 31% rise taking them to £234 profit. I'm confident this is just the start for Kibo, which has enormous long term potential.

Here's the effect of the week on the main portfolio



Weekly Change
Portfolio cost £36,372.15
+£178.91
Portfolio value (share price) £35,104.78 (-3%) +£28.65
Portfolio sell value (bid price - commission) £34,031.20 (-6.4%) +£134.46
Potential profits £2,421.22
+£34.30
Dividends £437.17
+£14.40
Profit from sales £2,809.51
+£178.95
Average monthly cash profit £365.07
+£12.78
(Sold stocks profit + Dividends - Fees / Months)
Avg annual % of current portfolio cost 12%

The £178.95 profit was from selling 1,000 of my TON:Titon Holdings shares to buy a load more AMYT:Amryt Pharma shares. That also explains the increase in portfolio cost of £178.91 as the profits were re-invested. Fat lot of good it did, with the Amryt shares dropping 10%. I still think the quality of the people involved in this company will see it come good in time.

Rare to see the increase in bid price substantially better than the rise in share price, suggesting a narrowing of the spread. One dividend this week from CMCL:Caledonia Mining of £14.24, and there was 16p back from AMYT:Amryt Pharma for the fractional difference when shares were consolidated, which I counted as a dividend.

The effect of all that was a slight increase in portfolio value and an increase of £12.78 in the average monthly profit. When I started out, I really didn't think that I'd be looking at £365 a month profit compared to the £40 a month interest I was earning. It's very encouraging.

The pension fund now looks like this



Weekly Change
Portfolio cost £11,318.28
+£6.61
Portfolio value (share price) £13,095.39 (+15.7%) -£19.61
Portfolio sell value (bid price - commission) £12,807.72 (+13.2%) -£57.71
Potential profits £1,756.74
-£14.29
Dividends £21.14
+£0
Profit from sales £699.89
+£8.03
Average monthly cash profit £139.89
-£5.01
(Sold stocks profit + Dividends - Fees / Months)
Avg annual % of current portfolio cost 14.8%

A massive profit of £8.03 from baling out of LLOY:Lloyds Bank enabled me to increase my holding in CAML:Central Asia Metals before the dividend ex-date. The Lloyds share price did drop following their results, but not as much as I had feared. Unfortunately Central Asia Metals dropped 3% this week so I'm no better off, but I will be when the 4.3% dividend appears.

The first week in a while that the SIPP has performed worse than the other portfolio. The main issue was shares slipping to loss, with ALM:Allied Minds, ARL:Atlantis Resources, JLG:John Laing Group and TRX:Tissue Regenix all increasing losses. AA:Alcoa have risen 7% and HGM:Highlind Gold 5% to help offset these losses. I'm hoping the dodgy performances are just a blip.

What does next week hold? The big hope next week is OPTI:Optibiotix Healthcare. There has been oodles of coverage in the national press this week, and there's an investor meeting today that could see the launch of important news. They are already up 4% making £23 profit, but next week could see the shares take off in a big way. I really wish I had spare cash to get some more. I've already come close to taking a loss in order to buy some, but can't bring myself to do it. I've also toyed with selling some GVC:GVC Holdings shares to take some profit, but with them about to enter the premium market and get picked up by FTSE 250 tracker funds, I daren't sell any yet. Maybe I'll take a close look at some of my in-profit shares to see if they are likely to outperform Optibiotix...

No comments:

Post a Comment